Suraksha posts Rs 12.58 cr profit as Q1 network expansion continues
Management said one hub and three spokes were commissioned in Q1, with further expansion planned across eastern and north-eastern India.
Filed 12 Aug 2026, 18:19 IST · after market close · SURAKSHA (SURAKSHA)
Key takeaways
- Standalone operations converted Rs 84.09 cr of revenue into Rs 28.92 cr of operating profit, for a 34.39% margin.
- Net profit was Rs 12.58 cr after Rs 3.63 cr of tax, with other income contributing Rs 1.56 cr to pre-tax profit.
- Management said Suraksha commissioned one hub and three spoke centres during Q1FY27.
Standalone profit reflects depreciation and interest charges
Suraksha reported standalone Q1FY27 revenue of Rs 84.09 cr and operating profit of Rs 28.92 cr. Depreciation of Rs 10.6 cr and interest of Rs 3.67 cr reduced operating profit to pre-tax profit of Rs 16.21 cr. Other income added Rs 1.56 cr, while tax was charged at a 22.39% rate. The filing was made after market close on 12 Aug 2026.
Hub-and-spoke rollout continued through the quarter
Management said the company commissioned one hub and three spoke centres in Q1FY27. It also said two hubs and three spoke centres were added in July and August, with a hub in Jharkhand commissioned and a hub in Tripura due to follow shortly. The presentation shows three hubs and six spokes launched to date, alongside four hubs and seven spokes upcoming.
Genomics positioned as a future business pillar
Management said it expects Suraksha Genomics to become a meaningful pillar of the business. The presentation lists capabilities spanning prenatal diagnostics, inherited disease and whole-exome sequencing, pharmacogenomics and oncology molecular panels. Management also identified whole-genome and metagenomic testing, AI-assisted variant interpretation and population-scale screening as the next horizon.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹84 cr |
| Other income | ₹2 cr |
| Expenses | ₹55 cr |
| Operating profit | ₹29 cr |
| Operating margin (%) | 34.39% |
| Interest | ₹4 cr |
| Depreciation | ₹11 cr |
| Profit before tax | ₹16 cr |
| Tax | ₹4 cr |
| Net profit | ₹13 cr |
| EPS (₹) | ₹2.42 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Suraksha commissioned one hub and three spoke centres during Q1 FY27.
Guidance & outlook
- Management expects Suraksha Genomics to become a meaningful pillar of the business.
- The company identifies whole genome, metagenomic, AI-assisted interpretation and population-scale screening as its next horizon.
Expansion
- The company added two hubs and three spoke centres in July and August.
- Suraksha commissioned a hub centre in Jharkhand and plans to follow with a hub in Tripura.
- The FY27 plan includes three hubs and six spokes launched to date, with four hubs and seven spokes upcoming.
- The company plans to identify key locations in Eastern and North-Eastern India for expansion.
New products
- Suraksha Genomics offers prenatal, inherited disease, pharmacogenomics and oncology molecular testing capabilities.
Competition
- Organized diagnostic players are gaining market share from standalone labs.
What to watch
- Whether standalone operating margin holds around 34.39%.
- Progress against the stated pipeline of four hubs and seven spokes upcoming.